Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EPS (Basic): 2023-2025

Historic EPS (Basic) for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$2.28.

  • Inhibrx Biosciences' EPS (Basic) rose 19.72% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.96, marking a year-over-year decrease of 110.76%. This contributed to the annual value of $114.01 for FY2024, which is 656.69% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' EPS (Basic) stood at -$2.28, which was down 23.24% from -$1.85 recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' EPS (Basic) peaked at $127.10 during Q2 2024, and registered a low of -$7.29 during Q4 2023.
  • Its 3-year average for EPS (Basic) is $9.04, with a median of -$3.61 in 2023.
  • As far as peak fluctuations go, Inhibrx Biosciences' EPS (Basic) skyrocketed by 2,930.73% in 2024, and later tumbled by 101.46% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' EPS (Basic) stood at -$7.29 in 2023, then spiked by 31.00% to -$5.03 in 2024, then rose by 19.72% to -$2.28 in 2025.
  • Its last three reported values are -$2.28 in Q3 2025, -$1.85 for Q2 2025, and -$2.80 during Q1 2025.